Drug Makers, Governments Sign Deal to Fight Drug-Resistant Infections
A groundbreaking agreement between the drug industry and governments to work together to fight drug-resistant "superbugs" is expected to be announced Thursday.
Under the deal, 74 drug makers, 11 diagnostic test makers, and nine industry groups pledge to work with each other and 16 countries to prevent and improve treatment of drug-resistant infections, the Associated Press reported.
These infections are a serious threat to millions of people worldwide and a number of factors contribute to the problem, including overuse of antibiotics, declining drug industry research, and few new medicines to combat bacteria, viruses, parasites and fungi.
The new deal -- scheduled to be announced at the World Economic Forum in Davos, Switzerland -- is the first to outline how the drug industry and governments should team up to prevent more drugs from becoming ineffective, to spur development of new medicines, and to provide the drugs to all people who need them, regardless of location or income, the AP reported.
Specific steps outlined in the agreement include: increasing access to antibiotics in countries worldwide; better education of doctors and nurses about appropriate antibiotic use; improved infection control through vaccination, preventive treatments and better hygiene; reduced use of antibiotics in livestock, and increased collaboration between drug company, university and government researchers.
"Antimicrobials are the backbone of modern medicine, and have played a key role in increasing life expectancy globally," Dr. Paul Stoffels, Johnson & Johnson's chief scientific officer, said in a statement, the AP reported.
"For the world to continue to have new antibiotics, we need investments in basic science and novel incentive models for industry R&D, and to protect our existing treatments, we need new frameworks for appropriate use," he explained.
Other companies included in the agreement are GlaxoSmithKline PLC, Novartis AG and Pfizer Inc. -- which make antimicrobial drugs and vaccines -- and Roche Group and Alere Inc., which make tests used to diagnose specific types of infections, the AP reported.
Posted: January 2016